Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

ARCH BIOPARTNERS SAFELY COMPLETES  EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL

GlobeNewswire March 17, 2020

IIROC Trading Halt - ARCH

Canada NewsWire March 16, 2020

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

GlobeNewswire March 4, 2020

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

GlobeNewswire February 21, 2020

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire February 6, 2020

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire February 4, 2020

Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial

GlobeNewswire December 18, 2019

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

GlobeNewswire December 4, 2019

Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

GlobeNewswire November 7, 2019

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

GlobeNewswire August 22, 2019

Arch Biopartners Announces Start of Phase I Human Trial for Metablok

GlobeNewswire June 19, 2019

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire May 22, 2019

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire May 17, 2019

Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

GlobeNewswire March 19, 2019

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

GlobeNewswire February 7, 2019

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire January 29, 2019

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire January 24, 2019

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

GlobeNewswire December 11, 2018

Arch Biopartners Provides Toxicology Update for Metablok

GlobeNewswire October 29, 2018

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

Canada NewsWire September 26, 2018